Does Vitamin K2 Actually Work? What the Evidence Shows

By Erin Rose · Published July 26, 2026 · Methodology · About Us

Informational summary of published research — not medical advice. If you take warfarin or another vitamin K antagonist, do not start K2 without your physician.

Ready to buy? See the best vitamin K2 picks, ranked by form quality and cost per day →

The verdict, by outcome

Vitamin K2 doesn't deserve one blanket yes-or-no. Bone and arterial stiffness have real but modest support; actual arterial calcification does not, and the warfarin risk sits apart from all of it:

If you're going to try it, this is what to buy

Any pick here applies to the bone and arterial-stiffness rows above, not to "cleaning out" arteries or the pharmaceutical MK-4 fracture protocol. NOW Foods MK-7 100mcg $0.22/day uses branded MenaQ7 — the all-trans, soy-free ingredient used in the trials cited above — at a dose inside their 90-200mcg range. For the same dose at lower cost, Nutricost MK-7 100mcg $0.07/day is a reasonable value alternative. Take it with a fatty meal, and if you're on warfarin, involve your doctor before starting either one. See every verified pick in the full vitamin K2 buying guide.

Check price →

Bone density: modest but real, and the trials don't fully agree

A 3-year trial of MK-7 at 180mcg/day slowed bone loss at the spine and femoral neck — though not at the total hip — in postmenopausal women (Knapen 2013, PMID: 23525894). That's a real, if partial, benefit.

A separate 3-year trial added MK-7 to vitamin D and calcium and found improved carboxylation markers, but no change in bone density at all (Rønn 2021, PMID: 33030563). Two well-run 3-year trials, two different bone outcomes. The honest summary: K2's bone evidence is modest and real, not a guaranteed or uniform benefit.

Arterial stiffness vs actual calcification: the distinction that matters

The same 3-year MK-7 trial design that showed a bone benefit also tested arterial stiffness. At 180mcg/day, it modestly improved stiffness and halved a vitamin-K-status marker (dp-ucMGP), mainly in women whose arteries were stiffer at baseline (Knapen 2015, PMID: 25694037). An observational study separately linked higher dietary K2 intake to lower coronary heart disease risk (Geleijnse 2004, PMID: 15514282).

Here's where the marketing runs well ahead of the data. Stiffness and biomarkers are not the same as calcification. Every recent, adequately powered trial that measured actual calcification came back negative: an aortic-valve trial (Diederichsen 2022, PMID: 35465686), a diabetic-artery trial (Zwakenberg 2019, PMID: 31387121), and a dialysis-patient trial (Naiyarakseree 2023, PMID: 37299386). K2 supports the system that routes calcium away from arteries. It does not dissolve calcium that's already there.

MK-4 and fractures: a different question, a different dose

A pooled analysis of older Japanese trials found high-dose MK-4 — 45mg/day, about 250 times a typical MK-7 dose — associated with fewer vertebral and hip fractures (Cockayne 2006, PMID: 16801507). That's a genuine signal, but several of those trials were open-label and used a pharmaceutical-scale dose. It doesn't establish that the MK-7 most people actually buy prevents fractures at a normal supplement dose.

The warfarin caution: the one risk that isn't slow-building

Everything above is a years-long story. The warfarin interaction is not. Vitamin K opposes warfarin, and MK-7 at supplement doses of 50mcg or more can interfere with it (Schurgers 2007, PMID: 17158229). Even small, inconsistent changes in vitamin K intake have destabilized warfarin patients (Couris 2006, PMID: 16941417). If you take warfarin, this is a today conversation with your prescriber, not a wait-and-see one.

What vitamin K2 does not do

• It does not clean out or reverse arterial calcification. The adequately powered calcification trials were negative across the board.
• It does not reliably change bone density on its own. One 3-year trial found a spine and femoral-neck benefit; another found none.
• It is not proven to prevent heart attacks or strokes. The arterial evidence is a stiffness and biomarker result, not a hard outcome.
• It is not safe to combine with warfarin unsupervised. Even one capsule can matter — this needs your doctor from day one.

Frequently asked questions

Related guides

• MK-7 vs MK-4 — why the form decides the dose, and the honest arterial evidence in full
• Vitamin K2 Dosage Guide — the 90-200mcg range and the warfarin rule
• Best Vitamin K2 Supplement — every verified pick, ranked by cost per day

Sources